Browsing Tag
Cambridge
19 posts
British Land (LSE: BLND) to acquire Life Science REIT in £150m science property deal
British Land to acquire Life Science REIT for £150M in a strategic science real estate deal. Find out how this reshapes the UK innovation leasing market.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Genfit abandons VS-01 in ACLF after safety scare—can a pivot to UCD rescue GNFT’s pipeline story?
Genfit ends VS-01 in ACLF and refocuses on UCD, trims spend, and extends runway beyond 2028. Find out what it means for GNFT stock and 2025 catalysts.
Ategenos unveils SmartPatch to tackle $528bn medication non-adherence crisis
Ategenos debuts SmartPatch, a first-of-its-kind connected patch tackling $528bn medication non-adherence with real-time, IoT-enabled monitoring.
Vyome completes merger with ReShape Lifesciences, to debut on Nasdaq as Vyome Holdings (HIND) on August 15
Vyome merges with ReShape Lifesciences, will trade on Nasdaq as Vyome Holdings (HIND) from August 15, focusing on immuno-inflammatory and rare diseases.
Novartis dodges Trump’s drug tariff blitz with $23bn US reshoring plan
Find out how Novartis plans to produce all key medicines in the US through a $23B investment in 10 new and expanded facilities nationwide.
Protecting Canada from space: How this C$72m contract to Spire Global could transform wildfire response
The Canadian Space Agency has assigned a C$72 million contract to Spire Global Canada, a subsidiary of Spire…
Darktrace to acquire Cado Security, enhancing AI-driven cloud cybersecurity solutions
Darktrace, a globally recognized leader in artificial intelligence (AI) for cybersecurity, has announced its proposed acquisition of Cado…
AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment…
Danaher wraps up $5.7bn acquisition of Abcam to bolster life sciences segment
Danaher Corporation (NYSE: DHR), a renowned global science and technology innovator, has announced the completion of its acquisition…